These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 6883351

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
    Citarella RV, Wallace RE, Murdock KC, Angier RB, Durr FE, Forbes M.
    Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
    [Abstract] [Full Text] [Related]

  • 5. Anthrapyrazoles, a new class of intercalating agents with high-level, broad spectrum activity against murine tumors.
    Leopold WR, Nelson JM, Plowman J, Jackson RC.
    Cancer Res; 1985 Nov; 45(11 Pt 1):5532-9. PubMed ID: 4053027
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Anticancer Drug Development: The Way Forward.
    Connors T.
    Oncologist; 1996 Nov; 1(3):180-181. PubMed ID: 10387985
    [Abstract] [Full Text] [Related]

  • 8. The preclinical new drug research program of the National Cancer Institute.
    Driscoll JS.
    Cancer Treat Rep; 1984 Jan; 68(1):63-76. PubMed ID: 6692438
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The National Cancer Institute antitumor drug discovery program, current and future perspectives: a commentary.
    Venditti JM.
    Cancer Treat Rep; 1983 Sep; 67(9):767-72. PubMed ID: 6883352
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Antitumor screening procedures of the National Cancer Institute.
    Schepartz SA.
    Jpn J Antibiot; 1977 Dec; 30 Suppl():35-40. PubMed ID: 612710
    [Abstract] [Full Text] [Related]

  • 14. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors.
    Koyanagi N, Nagasu T, Fujita F, Watanabe T, Tsukahara K, Funahashi Y, Fujita M, Taguchi T, Yoshino H, Kitoh K.
    Cancer Res; 1994 Apr 01; 54(7):1702-6. PubMed ID: 8137285
    [Abstract] [Full Text] [Related]

  • 15. Experimental evaluation of anthracycline analogs.
    Casazza AM.
    Cancer Treat Rep; 1979 May 01; 63(5):835-44. PubMed ID: 455325
    [Abstract] [Full Text] [Related]

  • 16. Human tumor testsystems: a new screening approach.
    Kraemer HP, Sedlacek HH.
    Behring Inst Mitt; 1986 Jun 01; (80):103-12. PubMed ID: 3753367
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of DMP 840: a novel bis-naphthalimide cytotoxic agent with human solid tumor xenograft selectivity.
    McRipley RJ, Burns-Horwitz PE, Czerniak PM, Diamond RJ, Diamond MA, Miller JL, Page RJ, Dexter DL, Chen SF, Sun JH.
    Cancer Res; 1994 Jan 01; 54(1):159-64. PubMed ID: 8261436
    [Abstract] [Full Text] [Related]

  • 18. Screening and evaluation of anticancer agents.
    Zee-Cheng RK, Cheng CC.
    Methods Find Exp Clin Pharmacol; 1988 Feb 01; 10(2):67-101. PubMed ID: 3283480
    [Abstract] [Full Text] [Related]

  • 19. Preclinical antitumor activity of bizelesin in mice.
    Carter CA, Waud WR, Li LH, DeKoning TF, McGovren JP, Plowman J.
    Clin Cancer Res; 1996 Jul 01; 2(7):1143-9. PubMed ID: 9816280
    [Abstract] [Full Text] [Related]

  • 20. [Application of nude mouse-human cancer xenograft system for sensitivity test of anticancer drugs].
    Fujita M, Taguchi T.
    Gan To Kagaku Ryoho; 1982 Apr 01; 9(4):606-15. PubMed ID: 7184418
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.